8-K: Anteris Reports Wider Loss, Secures $320M Capital

Anteris Technologies Global Corp. reported a significant increase in net loss for 2025, alongside a 29% revenue decline, but secured $320 million in early 2026 capital raises and advanced its pivotal DurAVR THV trial.

Summary

• Anteris Technologies Global Corp. reported revenues from ordinary activities of US$1,913 thousand for the year ended December 31, 2025, a 29% decrease from US$2,703 thousand in 2024.
• The company's loss from ordinary activities after tax increased by 24% to US$94,225 thousand in 2025, compared to US$75,967 thousand in 2024.
• Net tangible asset backing per share was ($0.01) as of December 31, 2025, a significant decrease from $1.74 as of December 31, 2024.
• Net operating cash outflows for the year ended December 31, 2025, were US$77.8 million, driven by increased clinical, regulatory, and manufacturing requirements for the PARADIGM Trial.
• Research and Development (R&D) expenses were US$69.1 million, primarily due to manufacturing upscaling, quality capabilities, R&D headcount increase, and PARADIGM Trial preparatory activities.
• Selling, general, and administrative expenses amounted to US$26.1 million for the year.
• The company initiated the global pivotal PARADIGM Trial for its DurAVR THV, following FDA Investigational Device Exemption (IDE) approval in the fourth quarter of 2025 for the United States.
• Favorable 30-day (100 patients) and 1-year (65 patients) clinical outcomes for DurAVR THV were reported from rolling cohorts of small annuli, symptomatic severe aortic stenosis patients.
• Anteris completed aggregate capital raises totaling US$320 million in early 2026, including a strategic investment from Medtronic, plc, to support the PARADIGM Trial and advance toward global commercialization.
• David Roberts and Gregory Moss were appointed as new independent directors to the Board of Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report; while the substantial capital raise and significant clinical progress are positive for long-term development, the notable increase in net loss and revenue decline indicate ongoing operational challenges and a high burn rate typical for a development-stage medical device company.

Positives

• Initiated the global pivotal PARADIGM Trial for DurAVR THV, a critical step towards commercialization.
• Received FDA Investigational Device Exemption (IDE) approval in Q4 2025 to commence the PARADIGM Trial in the United States.
• Reported favorable 30-day (100 patients) and 1-year (65 patients) clinical outcomes for DurAVR THV, demonstrating promising early results.
• Successfully treated 130 patients with DurAVR THV, including complex cases like de novo aortic stenosis and valve-in-valve replacements.
• Completed the first double DurAVR implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positions.
• Strengthened operational infrastructure, advanced quality management systems, and achieved ISO 13485 certification for DurAVR THV production.
• Completed aggregate capital raises totaling US$320 million in early 2026, including a strategic investment from Medtronic, plc, significantly bolstering financial resources for the PARADIGM Trial and commercialization.
• Appointed two new independent directors, David Roberts and Gregory Moss, enhancing corporate governance.

Negatives

• Revenues from ordinary activities decreased by 29% to US$1,913 thousand in 2025 from US$2,703 thousand in 2024.
• Loss from ordinary activities after tax increased by 24% to US$94,225 thousand in 2025 from US$75,967 thousand in 2024.
• Loss for the year attributable to members increased by 23% to US$94,144 thousand in 2025 from US$76,291 thousand in 2024.
• Net tangible asset backing per share became negative at ($0.01) as of December 31, 2025, down from $1.74 in 2024.
• Net operating cash outflows were substantial at US$77.8 million for the year ended December 31, 2025, indicating a high burn rate.
• All US$80.0 million net proceeds from the December 2024 IPO were fully utilized as of December 31, 2025.

Risks

• Forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under Risk Factors in the Annual Report on Form 10-K for the fiscal period ended December 31, 2025.

Future Outlook

The company is focused on advancing the global pivotal PARADIGM Trial for its DurAVR THV, with the aim of achieving global commercialization of the DurAVR THV System. Management anticipates becoming a leader in next-generation TAVR, building on clinical evidence and a strengthened balance sheet.

Management Comments

• "2025 was a pivotal year for Anteris, advancing DurAVR with disciplined execution, strengthening our clinical foundation, and positioning the company for long term leadership in structural heart."
• "We converted strategy into measurable progress, reinforcing our competitive position and accelerating our path toward commercial readiness."
• "The progress achieved in 2025 has strengthened our foundation and sharpened our trajectory toward becoming a leader in next-generation TAVR."
• "We remained focused on what matters most; advancing clinical evidence, strengthening our balance sheet, and building sustainable long-term value."

Industry Context

StockSavvy.ai notes Anteris is positioning itself as an innovator in the highly competitive structural heart market, specifically within the transcatheter aortic valve replacement (TAVR) segment, with its unique biomimetic DurAVR THV. The initiation of a pivotal randomized controlled trial (PARADIGM) against commercially available TAVRs, coupled with a significant strategic investment from Medtronic, plc, signals growing industry validation and potential for disruption in a market dominated by established players.

Comparison to Industry Standards

• The PARADIGM Trial is designed as a head-to-head study to evaluate the safety and effectiveness of the DurAVR THV compared to commercially available transcatheter aortic valve replacements (TAVRs).
• The filing does not provide specific comparative financial or operational metrics against named competitors or industry benchmarks in this report.

Management Changes

Corporate Governance

Related Party Transactions

• During the fourth quarter of 2025, aggregate payments to related parties and their associates (including director fees, company secretarial fees, CEO, President, and CFO remuneration) totaled US$460 thousand, included in cash flows from operating activities.

Stakeholder Impact

• Shareholders face dilution from the recent capital raise but benefit from the significant funding secured for the pivotal clinical trial and strategic investment from Medtronic, which de-risks future development.
• Employees benefit from continued investment in R&D, manufacturing, and clinical teams, supporting job stability and growth opportunities.
• Patients with severe aortic stenosis stand to benefit from the continued development and potential commercialization of the DurAVR THV, offering a new treatment option.
• Creditors may view the substantial capital raise as a positive, improving the company's liquidity and ability to meet obligations.

Next Steps

• Continue active recruitment and enrollment for the global pivotal PARADIGM Trial.
• Advance manufacturing scale-up to support ongoing clinical activities.
• Progress toward global commercialization of the DurAVR THV System.

Key Dates

Recommendation

The company reported a substantial increase in net loss and a decline in revenue, indicating a high cash burn rate typical for a development-stage medical device company. However, the successful completion of a $320 million capital raise, including a strategic investment from Medtronic, significantly de-risks the funding for the pivotal PARADIGM trial. Clinical progress with the DurAVR THV and FDA IDE approval are positive long-term indicators. Given the mixed financial performance against strong strategic and clinical advancements, a "hold" recommendation is appropriate as investors await further clinical trial data and progress towards commercialization.

Keywords

Anteris Technologies, DurAVR THV, Aortic Stenosis, TAVR, Transcatheter Heart Valve, Medical Devices, Structural Heart, FDA IDE, PARADIGM Trial, ADAPT tissue, Medtronic, Clinical Trials, Biomimetic Valve